CCM
CLVS

Camber Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Camber Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,500,000
Closed -$37.2M – 35
2019
Q1 		$37.2M Sell
1,500,000
-1,300,000
-46% -$32.6M 1.86% 22
2018
Q4 		$50.3M Buy
2,800,000
+1,050,000
+60% +$21.5M 2.39% 17
2018
Q3 		$51.4M Buy
1,750,000
+750,000
+75% +$29M 2.2% 18
2018
Q2 		$45.5M Buy
1,000,000
+175,000
+21% +$8.51M 1.75% 26
2018
Q1 		$43.6M Buy
825,000
+225,000
+38% +$13.1M 2.14% 21
2017
Q4 		$40.8M Buy
600,000
+400,000
+200% +$28M 2% 19
2017
Q3 		$16.5M Buy
+200,000
New +$15.9M 1.04% 21

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Camber Capital Management's CLVS Position: Q2 2019 in Review

Camber Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 1,500,000 shares — an estimated $37.2M sold.

Camber Capital Management first reported a position in CLVS in Q3 2017 and held it in 7 quarters. The position peaked at $51.4M in Q3 2018. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Camber Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Camber Capital Management sold 1,500,000 Clovis Oncology, Inc. shares in Q2 2019, an estimated $37.2M.
  • Camber Capital Management first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 7 quarters.
  • Camber Capital Management's Clovis Oncology, Inc. position peaked at $51.4M in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Camber Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.